Zacks Investment Ideas is featuring Eli Lilly and Altria as investors rotate into defensive sectors ahead of a pivotal week. The Federal Reserve under new Chair Kevin Warsh has shifted its outlook, with the dot plot now projecting a rate hike and futures pricing a 62% chance of tightening in September. The June jobs report due Thursday could harden the hawkish case if strong, while a soft print may revive hopes for a hold. Money has flowed into consumer staples and healthcare, with Eli Lilly offering growth through its newly approved oral GLP-1 pill Foundayo and Altria providing a roughly 6% dividend yield and a 57-year streak of increases.
Eli Lilly and CompanyEli Lilly's newly approved oral GLP-1 pill Foundayo drives growth, attracting defensive rotation inflows.
Altria GroupAltria offers a roughly 6% dividend yield and a 57-year streak of increases, appealing to defensive investors.